(Q38662343)

5 September 2017

title

Keeping up the balance: role of HDACs in cardiac proteostasis and therapeutic implications for atrial fibrillation (English)

1 reference

5 September 2017

1 reference

3

1 reference

5 September 2017

Deli Zhang

1

1 reference

5 September 2017

Xu Hu

series ordinal

2

1 reference

5 September 2017

Bianca J J M Brundel

series ordinal

4

1 reference

5 September 2017

language of work or name

1 reference

8 December 2015

1 reference

5 September 2017

published in

Cardiovascular Research

1 reference

5 September 2017

volume

109

1 reference

5 September 2017

issue

4

1 reference

5 September 2017

page(s)

519-526

1 reference

Adapting proteostasis for disease intervention

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Biological and chemical approaches to diseases of proteostasis deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Reviving the protein quality control system: therapeutic target for cardiac disease in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Loss of proteostatic control as a substrate for atrial fibrillation: a novel target for upstream therapy by heat shock proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

New antiarrhythmic drugs for treatment of atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Current concepts in the pathogenesis of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Connexins, conduction, and atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Epidemiological profile of atrial fibrillation: a contemporary perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Atrial remodeling and atrial fibrillation: mechanisms and implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Histological substrate of atrial biopsies in patients with lone atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

HSPB1, HSPB6, HSPB7 and HSPB8 protect against RhoA GTPase-induced remodeling in tachypaced atrial myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Effects of different small HSPB members on contractile dysfunction and structural changes in a Drosophila melanogaster model for Atrial Fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Heat shock proteins as molecular targets for intervention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Therapeutic potential for HDAC inhibitors in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

HDAC3-dependent reversible lysine acetylation of cardiac myosin heavy chain isoforms modulates their enzymatic and motor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Targeting histone deacetylases for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

The biology and therapeutic implications of HDACs in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Left atrial transcriptional changes associated with atrial fibrillation susceptibility and persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Dedifferentiation of atrial myocytes during atrial fibrillation: role of fibroblast proliferation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Contrasting gene expression profiles in two canine models of atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Transcriptional remodeling of rapidly stimulated HL-1 atrial myocytes exhibits concordance with human atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Effects of chronic atrial fibrillation on active and passive force generation in human atrial myofibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Proteomic analysis of post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Lysine acetylation: codified crosstalk with other posttranslational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Histone deacetylase inhibition reduces pulmonary vein arrhythmogenesis through calcium regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Is autophagy a double-edged sword for the heart?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Cardiac autophagy is a maladaptive response to hemodynamic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Non-sirtuin histone deacetylases in the control of cardiac aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Aging and disease: connections to sirtuins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Endothelin-stimulated human B-type natriuretic peptide gene expression is mediated by Yin Yang 1 in association with histone deacetylase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Modulation of smooth muscle gene expression by association of histone acetyltransferases and deacetylases with myocardin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Chromatin regulation by Brg1 underlies heart muscle development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

HDAC6 modulates cell motility by altering the acetylation level of cortactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Induction of heat shock response protects the heart against atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Contraction due to microtubule disruption is associated with increased phosphorylation of myosin regulatory light chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Inactivation of L-type Ca channels in embryonic chick ventricle cells: dependence on the cytoskeletal agents colchicine and taxol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Effect of cytoskeleton disruptors on L-type Ca channel distribution in rat ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Proteolysis of tubulin and microtubule-associated proteins 1 and 2 by calpain I and II. Difference in sensitivity of assembled and disassembled microtubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVV265

21 January 2018

Identifiers

DOI

10.1093/CVR/CVV265

1 reference

5 September 2017

1 reference